The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
p53 Expression in B-Cell Chronic Lymphocytic Leukemia: A Marker of Disease Progression and Poor Prognosis
Abstract
We have analyzed by immunocytochemistry (ICC) the frequency of p53 protein expression in 181 cases of B-cell chronic lymphocytic leukemia (CLL) followed at a single institution to assess the relationship between p53 and the clinical and morphological features of the disease, as well as the possible involvement of this protein in the pathogenesis of the more aggressive forms of CLL. The overall frequency of p53 protein positivity in CLL was 15% (27 of 181 cases). There were no significant differences in age, sex, absolute lymphocyte count, or lymphocyte doubling time between p53-positive and -negative patients. By contrast, p53-positive patients had a significantly higher percentage of prolymphocytes (P = .002) and a significantly lower percentage of residual CD3-positive T lymphocytes (P = .0001). No correlation was found between the percentage of p53-positive cells and the percentage of cells in cycle assessed by the monoclonal antibody Ki-67. When the percentage of p53 positivity was correlated with the clinical stage of the disease, the proportion of p53-positive cases increased significantly from Binet's stage A (8 of 108; 7.4%), to stage B (12 of 49; 24.4%) and C (7 of 24; 29.2%) (P = .002). p53 positivity correlated also with the phase of the disease, showing a low expression at diagnosis (8 of 112; 7.1%) and a significantly higher expression in patients studied during the course of the disease (7 of 35; 20%) and, to a further extent, with disease progression (12 of 34; 35.3%) (P = .0001). The association of p53 protein expression with mutations in the gene was confirmed by direct sequence of the entire cDNA in 15 of the 17 ICC positive cases tested (88%). A significantly shorter treatment-free interval from diagnosis (P = .003) and a poorer response to therapy (P = .007) was observed in p53-positive compared with p53-negative patients. Overall survival from the time of diagnosis, as well as from the time of p53 protein analysis, was significantly shorter in patients with p53 protein expression (P = .03 and .0001, respectively). Moreover, in multivariate analysis, p53 expression and stage C were independently associated with a short survival. The results of this study indicate that in CLL the expression of the p53 protein, analyzed by a simple and reliable immunocytochemical method, is strongly associated with p53 gene mutations, a morphological variant (CLL with >10% prolymphocytes), advanced clinical stage, progressive disease, poor response to therapy, and short survival.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
p53 Mutations in Human Cancers
Hollstein, M., Sidransky, D., Vogelstein, B., & Harris, C. C. (1991) · Science · doi:10.1126/science.1905840 · Cited by 8,018
Lane, D. P. (1992) · Nature · doi:10.1038/358015a0 · Cited by 5,138
Cited by
Byrd, J. C. (2003) · Blood · doi:10.1182/blood-2002-04-1258 · Cited by 571
Alemtuzumab Compared With Chlorambucil As First-Line Therapy for Chronic Lymphocytic Leukemia
Hillmen, P., Skotnicki, A. B., Robak, T., Jaksic, B., Dmoszynska, A., Wu, J., Sirard, C., & Mayer, J. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.9098 · Cited by 561
Lozanski, G., Heerema, N. A., Flinn, I. W., Smith, L., Harbison, J., Webb, J., Moran, M., Lucas, M., Lin, T., Hackbarth, M. L., et al. (2004) · Blood · doi:10.1182/blood-2003-10-3729 · Cited by 398
Inactivation of ataxia telangiectasia mutated gene in B-cell chronic lymphocytic leukaemia
Stankovic, T., Weber, P., Stewart, G., Bedenham, T., Murray, J., Byrd, P. J., Moss, P. A., & Taylor, A. M. R. (1999) · The Lancet · doi:10.1016/s0140-6736(98)10117-4 · Cited by 356
Grever, M. R., Lucas, D. M., Dewald, G. W., Neuberg, D. S., Reed, J. C., Kitada, S., Flinn, I. W., Tallman, M. S., Appelbaum, F. R., Larson, R. A., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.08.3089 · Cited by 353
Metadata
- Authors
- Cordone, I., Masi, S., Mauro, F. R., Soddu, S., Morsilli, O., Valentini, T., Vegna, M. L., Guglielmi, C., Mancini, F., Giuliacci, S., Sacchi, A., Mandelli, F., & Foa, R.
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 1998-06-01
- Volume
- 91
- Issue
- 11
- Pages
- 4342-4349
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- OpenAlex
- W4254567638
- Cited by
- 215
- References
- 2
- FWCI
- 7.93
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: p53 Expression in B-Cell Chronic Lymphocytic Leukemia: A Marker of Disease Progression and Poor Prognosis. https://app.cochat.ai/papers/10.1182/blood.v91.11.4342
- The paper
- Cordone, I., Masi, S., Mauro, F. R., Soddu, S., Morsilli, O., Valentini, T., Vegna, M. L., Guglielmi, C., Mancini, F., Giuliacci, S., Sacchi, A., Mandelli, F., & Foa, R. (1998). p53 Expression in B-Cell Chronic Lymphocytic Leukemia: A Marker of Disease Progression and Poor Prognosis. Blood. https://doi.org/10.1182/blood.v91.11.4342
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.